ProShare Advisors LLC increased its holdings in Audentes Therapeutics, Inc. (NASDAQ:BOLD) by 27.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,581 shares of the biotechnology company’s stock after acquiring an additional 3,324 shares during the quarter. ProShare Advisors LLC owned about 0.06% of Audentes Therapeutics worth $298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Audentes Therapeutics by 278.5% in the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 5,700 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 6,384 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Audentes Therapeutics in the 1st quarter worth about $184,000. State of Wisconsin Investment Board bought a new position in shares of Audentes Therapeutics in the 2nd quarter worth about $210,000. Finally, Rhumbline Advisers bought a new position in shares of Audentes Therapeutics in the 2nd quarter worth about $252,000. Institutional investors own 77.09% of the company’s stock.
TRADEMARK VIOLATION WARNING: “ProShare Advisors LLC Raises Position in Audentes Therapeutics, Inc. (BOLD)” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2017/10/11/proshare-advisors-llc-raises-position-in-audentes-therapeutics-inc-bold.html.
In other Audentes Therapeutics news, SVP Mary Newman sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the transaction, the senior vice president now directly owns 10,000 shares in the company, valued at $200,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Nagler sold 3,750 shares of the business’s stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $30.00, for a total transaction of $112,500.00. Following the completion of the transaction, the senior vice president now owns 3,750 shares of the company’s stock, valued at $112,500. The disclosure for this sale can be found here. Insiders sold 781,500 shares of company stock valued at $21,743,730 over the last quarter. 47.30% of the stock is currently owned by corporate insiders.
Shares of Audentes Therapeutics, Inc. (BOLD) opened at 26.69 on Wednesday. The company’s 50-day moving average is $26.73 and its 200 day moving average is $26.73. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $33.43. The stock’s market capitalization is $741.55 million.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.10). Equities research analysts predict that Audentes Therapeutics, Inc. will post ($3.50) earnings per share for the current year.
Several research analysts recently issued reports on BOLD shares. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Monday, July 17th. ValuEngine upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Bank of America Corporation reiterated a “buy” rating and issued a $33.00 price target (up from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Finally, Evercore ISI started coverage on shares of Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $24.17.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics, Inc. (NASDAQ:BOLD).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.